Neovascularization of ischemic myocardium by human bone-marrow–derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function

By Alfred A Kocher, M. Schuster, M. Szabolcs, S. Takuma, D. Burkhoff, Jie Wang, S. Homma, N. Edwards, S. Itescu. Nature Medicine, 2001

2,734 citations recorded by the source corpus.

Subfields: Biomaterials, Cardiology and Cardiovascular Medicine, Surgery

View Paper: https://www.semanticscholar.org/paper/b9641692bee80c2942700a7d608696a1c6cccc3d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. E. Olson
2. Joseph A. Hill
3. J. Willerson

In Surgery

1. J. Willerson
2. Nikolaos G. Frangogiannis

Citations in the corpus

• Clonally expanded novel multipotent stem cells from human bone marrow regenerate myocardium after myocardial infarction. (2005, methodology): “Therapeutic application of BM-derived stem cells has demonstrated that endothelial progenitor cells (14), angioblasts (15), or CD34+ cells (16) transplanted into ischemic myocardium incorporate into foci of neovascularization and have a favorable impact on Nonstandard abbreviations used: ANP, atrial”
• Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells. (2005, background): “Supplementary to the improvement of neovascularization, injection of EPC also significantly improved cardiac function in animal models [10,11].”